# Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

> **NCT07125547** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Ureteral Cancer
- Neoadjuvant Therapy
- PD-1 Inhibitor
- Kidney-sparing
- Tislelizumab
- Nab-paclitaxel

## Interventions

- **DRUG:** PD-1 inhibitior
- **DRUG:** Nab-paclitaxel
- **PROCEDURE:** distal ureterectomy

## Key facts

- **NCT ID:** NCT07125547
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-05
- **Primary completion:** 2026-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07125547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07125547, "Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07125547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*